@article{19b117e4dfe640018e06f59a08074d40,
title = "Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response",
author = "Jallouk, {Andrew P.} and Sushanth Gouni and Jason Westin and Lei Feng and Haleigh Mistry and Steiner, {Raphael E.} and Jinsu James and Mansoor Noorani and Sandra Horowitz and Nahum Puebla-Osorio and Fayad, {Luis E.} and Iyer, {Swaminathan P.} and Misha Hawkins and Flowers, {Christopher R.} and Sairah Ahmed and Nastoupil, {Loretta J.} and Partow Kebriaei and Shpall, {Elizabeth J.} and Neelapu, {Sattva S.} and Yago Nieto and Paolo Strati",
note = "Funding Information: This research is supported in part by The University of Texas MD Anderson Cancer Center Support Grant from the National Institutes of Health (P30 CA016672). PS salary is supported by the Lymphoma Research Foundation Career Development Award, the Leukemia Lymphoma Society Scholar in Clinical Research Career Development Program, the Sabin Fellowship Award, and by an R21 NIH grant. Funding Information: PS is a consultant for Kite-Gilead, Roche-Genentech, Hutchinson MediPharma, ADC Therapeutics, Incyte Morphosis and TG Therapeutics; and received research funds from Sobi Pharmaceuticals, Astrazeneca-Acerta, ALX Oncology and ADC Therapeutics. RES has received research funding from Seagen, BMS,",
year = "2023",
month = apr,
doi = "10.3324/haematol.2022.281954",
language = "English (US)",
volume = "108",
pages = "1163--1167",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "4",
}